Sunshine Biopharma Inc. (SBFM) Stock Price & Analysis
Sunshine Biopharma Inc. (SBFM) fell 6.17% to USD 2.28 as of June 10, 2026 at 10:45 UTC, according to Nexqual real-time market data.
SBFM last closed at USD 2.43; the session ranged USD 2.06–2.35 on volume of 265,127 shares. Market capitalization is $4.84M, with a 52-week range of USD 2.06–24.3 (NCM). Source: Nexqual, June 10, 2026 at 10:45 UTC.
Key Statistics (as of June 10, 2026 at 10:45 UTC)
| Price | USD 2.28 |
|---|---|
| Change | ▼ 6.17% (down) |
| Previous Close | USD 2.43 |
| Open | USD 2.32 |
| Day Range | USD 2.06 – 2.35 |
| 52-Week Range | USD 2.06 – 24.3 |
| Volume | 265,127 shares |
| Market Cap | $4.84M |
| Exchange | NCM |
Technical Analysis (SBFM)
Nexqual's technical model rates SBFM "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 10:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.15 (neutral) |
| vs SMA50 | Below (USD 7.91) |
| MACD | -1.74 (negative) |
Analyst Ratings (SBFM)
Wall Street analysts rate SBFM "Strong Buy" based on 1 analysts, with a mean price target of USD 56 (range USD 56–56), per Nexqual as of June 10, 2026 at 10:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 56 |
| High Target | USD 56 |
| Low Target | USD 56 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SBFM)
| Revenue Estimate | $8.60M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.5 vs est -1.6 ▼ miss |
| 2025-12-31 | USD -4.6 vs est -2.7 ▼ miss |
| 2025-09-30 | USD -1.9 vs est -1.3 ▼ miss |
| 2025-06-30 | USD -3.9 vs est -1.1 ▼ miss |
Source: Nexqual, June 10, 2026 at 10:45 UTC.
Financials & Fundamentals (SBFM)
| Total Revenue | $35.49M |
|---|---|
| Revenue Growth (YoY) | -9.10% |
| Gross Margin | +32.98% |
| Operating Margin | -17.25% |
| Profit Margin | -17.02% |
| ROE | -27.32% |
| Debt / Equity | 3.46 |
| Current Ratio | 4.22 |
| Total Cash | $6.91M |
| Total Debt | $744,840 |
| Free Cash Flow | $-4.71M |
Source: Nexqual, June 10, 2026 at 10:45 UTC.
Financial Health Score (SBFM)
Nexqual rates Sunshine Biopharma Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:45 UTC.
| Growth | Mixed — Revenue +4.1% YoY (annual), slow |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -27%, ROA -10.0% |
Ownership (SBFM)
| Insider Ownership | +0.48% |
|---|---|
| Institutional Ownership | +12.87% |
| Shares Outstanding | 2.12M |
| Float | 497,436 |
| Short % of Float | +6.83% |
Source: Nexqual, June 10, 2026 at 10:45 UTC.
Leadership (SBFM)
Sunshine Biopharma Inc. is led by Steve N. Slilaty (age 73), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 10:45 UTC.
| Chairman, President & CEO | Steve N. Slilaty (age 73) |
|---|---|
| CFO, Secretary & Director | Camille Sebaaly (age 66) |
| President of Sunshine Bio Investments Inc | Robert G. Ferreira (age 63) |
Major Backers & Investors (SBFM)
Notable institutional backers of Sunshine Biopharma Inc. include Citadel, Two Sigma Securities, LLC, according to Nexqual as of June 10, 2026 at 10:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 0.22% |
| Two Sigma Securities, LLC | 0.11% |
Source: Nexqual, June 10, 2026 at 10:45 UTC.
From Sunshine Biopharma Inc.'s Latest SEC 10-K Filing (filed 2026-04-03)
Key Strengths & Strategy (as disclosed to the SEC)
- As of the date of the filing of this report, we have not made any filings with the FDA or other regulatory bodies in other jurisdictions in connection with our proprietary drugs in development.   In respect of OTC supplements, the FDA regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution, and sale of such products, while the Federal Trade Commission ("FTC") regulates marketing and advertising claims.
- Our personnel, together with outside consultants develop and place ads on various media platforms and manage our Amazon.ca account.             Competition   According to IMARC Group , the Canadian generic pharmaceuticals market was valued at approximately $10.4 billion USD in 2024 and is expected to grow to $19.7 billion USD by 2033.
- As of the date of this report, we believe Essential•9™ is the only Essential Amino Acid supplement that comprises all 9 essential amino acids in capsule form.   Workforce   As of the date of this report, we have a total of 50 employees, all of whom are full-time.   Presently, our proprietary drug development activities are subcontracted out to specialized service providers in the U.S., Canada and overseas.
Partnerships
- On April 20, 2022, we filed a provisional patent application in the United States covering our K1.1 mRNA molecules.           In November 2022, we concluded an agreement with a specialized commercial partner for the purposes of formulating our K1.1 mRNA molecules into specific lipid nanoparticles for use in test animals including xenograft mice.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| CELZ | Creative Medical Technology Hol | USD 2.18 | ▲ 5.83% |
| AREB | American Rebel Holdings, Inc. | USD 0.1 | ▼ 13.62% |
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:45 UTC. This page is informational and not investment advice.